Krebs Biochemicals [KREBSBIO] vs Divi's Laboratories [DIVISLAB] Detailed Stock Comparison

Krebs Biochemicals & Industries Limited

NSE
Loading...

Divi's Laboratories Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Krebs Biochemicals & Industries Limited wins in 5 metrics, Divi's Laboratories Ltd. wins in 13 metrics, with 0 ties. Divi's Laboratories Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Krebs Biochemicals & Industries Limited Divi's Laboratories Ltd. Better
P/E Ratio (TTM) -4.73 67.11 Divi's Laboratories Ltd.
Price-to-Book Ratio -0.79 10.82 Divi's Laboratories Ltd.
Debt-to-Equity Ratio -1.38 0.58 Divi's Laboratories Ltd.
PEG Ratio 0.08 4.63 Krebs Biochemicals & Industries Limited
EV/EBITDA -35.46 48.63 Divi's Laboratories Ltd.
Profit Margin (TTM) -99.30% 24.04% Divi's Laboratories Ltd.
Operating Margin (TTM) -18.33% 29.65% Divi's Laboratories Ltd.
EBITDA Margin (TTM) N/A 29.65% N/A
Return on Equity 18.42% 14.64% Krebs Biochemicals & Industries Limited
Return on Assets (TTM) -15.94% 12.94% Divi's Laboratories Ltd.
Free Cash Flow (TTM) $-114.54M $2.15B Divi's Laboratories Ltd.
Dividend Yield N/A 0.91% N/A
1-Year Return -13.55% 0.83% Divi's Laboratories Ltd.
Price-to-Sales Ratio (TTM) 5.62 16.18 Krebs Biochemicals & Industries Limited
Enterprise Value $3.51B $1,635.46B Divi's Laboratories Ltd.
EV/Revenue Ratio 15.23 15.86 Krebs Biochemicals & Industries Limited
Gross Profit Margin (TTM) 99.98% 63.71% Krebs Biochemicals & Industries Limited
Revenue per Share (TTM) $11 $388 Divi's Laboratories Ltd.
Earnings per Share (Diluted) $-10.60 $93.66 Divi's Laboratories Ltd.
Beta (Stock Volatility) 0.45 0.19 Divi's Laboratories Ltd.

Krebs Biochemicals & Industries Limited vs Divi's Laboratories Ltd. Stock Performance Analysis

Loading Price Chart...

KREBSBIO
DIVISLAB

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Krebs Biochemicals & Industries Limited2.57%-6.22%7.58%21.69%-0.99%-8.61%
Divi's Laboratories Ltd.0.30%-3.25%-0.65%4.12%1.88%3.66%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Krebs Biochemicals & Industries Limited-13.55%2.05%-46.83%-33.10%-33.10%-33.10%
Divi's Laboratories Ltd.0.83%89.86%56.44%484.44%1,625.50%9,907.51%

Performance & Financial Health Analysis: Krebs Biochemicals & Industries Limited vs Divi's Laboratories Ltd.

MetricKREBSBIODIVISLAB
Market Information
Market Cap i₹1.29B₹1.69T
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i9,952253,443
90 Day Avg. Volume i33,787283,911
Last Close₹65.54₹6,596.50
52 Week Range₹38.33 - ₹113.50₹5,636.50 - ₹7,071.50
% from 52W High-42.26%-6.72%
All-Time High₹227.90 (Dec 27, 2021)₹7,071.50 (Jul 08, 2025)
% from All-Time High-71.24%-6.72%
Growth Metrics
Quarterly Revenue Growth-0.37%0.12%
Quarterly Earnings Growth-0.37%-0.01%
Financial Health
Profit Margin (TTM) i-0.99%0.24%
Operating Margin (TTM) i-0.18%0.30%
Return on Equity (TTM) i0.18%0.15%
Debt to Equity (MRQ) i-1.380.58
Cash & Liquidity
Book Value per Share (MRQ)₹-74.59₹580.95
Cash per Share (MRQ)₹0.07₹122.95
Operating Cash Flow (TTM) i₹-132,808,000₹19.67B
Levered Free Cash Flow (TTM) i₹-269,393,000₹21.91B
Dividends
Last 12-Month Dividend Yield iN/A0.91%
Last 12-Month Dividend iN/A₹60.00

Valuation & Enterprise Metrics Analysis: Krebs Biochemicals & Industries Limited vs Divi's Laboratories Ltd.

MetricKREBSBIO (Apr 24, 2026)DIVISLAB (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i-4.7367.11
Forward P/E iN/A53.75
PEG Ratio i0.084.63
Price to Sales (TTM) i5.6216.18
Price to Book (MRQ) i-0.7910.82
Market Capitalization
Market Capitalization i₹1.29B₹1.69T
Enterprise Value i₹3.51B₹1.64T
Enterprise Value Metrics
Enterprise to Revenue i15.2315.86
Enterprise to EBITDA i-35.4648.63
Risk & Other Metrics
Beta i0.450.19
Book Value per Share (MRQ) i₹-74.59₹580.95

Financial Statements Comparison: Krebs Biochemicals & Industries Limited vs Divi's Laboratories Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricKREBSBIO (2025)DIVISLAB (2025)
Revenue/Sales i433.12M93.25B
Cost of Goods Sold i269.66M38.70B
COGS % of Revenue i62.3%41.5%
Gross Profit i163.46M54.55B
Gross Margin i37.7%58.5%
Research & Development iN/A270.00M
Operating Income (EBIT) i-213.02M25.71B
Operating Margin i-49.2%27.6%
EBITDA i-144.49M33.19B
EBITDA Margin i-33.4%35.6%
Pre-Tax Income i-269.24M29.16B
Pre-Tax Income % of Revenue i-62.2%31.3%
Income Tax i153,0007.25B
Income Tax % of Revenue i0.0%7.8%
Net Income (Profit) i-269.39M21.91B
Profit Margin i-62.2%23.5%

Balance Sheet & Liquidity Metrics

MetricKREBSBIO (2025)DIVISLAB (2025)
Cash & Equivalents i234,0004.15B
Total Current Assets i102.59M100.81B
Total Current Assets % of Revenue i23.7%108.1%
Total Current Liabilities i1.04B14.52B
Total Current Liabilities % of Revenue i239.0%15.6%
Long-Term Debt i2.06B20.00M
Long-Term Debt % of Revenue i476.2%0.0%
Total Shareholders Equity i-1.46B149.69B
Retained Earnings i-2.97B134.00B
Retained Earnings % of Revenue i-686.3%143.7%
Property, Plant & Equipment i223.53M3.19B

Cash Flow Statement Comparison

MetricKREBSBIO (2025)DIVISLAB (2025)
Operating Cash Flow i-132.81M19.67B
Operating Cash Flow % of Revenue i-30.7%21.1%
Capital Expenditures i-34.00M-14.38B
Free Cash Flow i-114.54M2.15B
FCF Margin i-26.4%2.3%
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricKREBSBIODIVISLAB
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i21.56M265.47M
Float Shares i4.07M117.72M
% Held by Insiders i77.55%52.04%
% Held by Institutions i0.00%28.65%
% Held by Public i22.45%19.31%

Dividend Analysis & Yield Comparison: Krebs Biochemicals & Industries Limited vs Divi's Laboratories Ltd.

MetricKREBSBIODIVISLAB
Last 12-Month Dividend iN/A₹60.00
Last 12-Month Dividend Yield iN/A0.91%
3-Year Avg Annual Dividend iN/A₹50.00
3-Year Avg Dividend Yield iN/A0.70%
3-Year Total Dividends iN/A₹150.00
Ex-Dividend DateN/AJul 25, 2025